Hovav Nechushtan

Summary

Affiliation: Hadassah University Hospital
Country: Israel

Publications

  1. pmc A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer
    Hovav Nechushtan
    Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Oncologist 20:366-7. 2015
  2. doi request reprint A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients
    Hovav Nechushtan
    Oncology Dept, Hadassah Hebrew University Medical Center, Israel Electronic address
    Breast 23:435-8. 2014
  3. doi request reprint The complexity of the complicity of mast cells in cancer
    Hovav Nechushtan
    Oncology, Hadassah Hebrew University Medical Center, Ein Kerem POB 12000, 91120 Jerusalem, Israel
    Int J Biochem Cell Biol 42:551-4. 2010
  4. pmc Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations
    Hovav Nechushtan
    Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    BMC Cancer 9:60. 2009
  5. pmc New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer
    Benjamin Nisman
    Department of Oncology, Hadassah and Hebrew University Medical Centre, P O Box 12000, Jerusalem 91120, Israel
    Br J Cancer 114:469-76. 2016
  6. doi request reprint Transcription factor E3, a major regulator of mast cell-mediated allergic response
    Zohar Yagil
    Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel Canada, Hebrew University Hadassah Medical School, Jerusalem, Israel
    J Allergy Clin Immunol 129:1357-1366.e5. 2012
  7. ncbi request reprint Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver
    Benjamin Nisman
    Department of Oncology, Hadassah and Hebrew University Medical Center, Jerusalem, Israel
    Anticancer Res 36:1791-7. 2016
  8. doi request reprint Mitochondrial STAT3 plays a major role in IgE-antigen-mediated mast cell exocytosis
    Tal Hadad Erlich
    Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel Canada, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
    J Allergy Clin Immunol 134:460-9. 2014
  9. doi request reprint Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report
    Benjamin Nisman
    Department of Oncology, Hadassah and Hebrew University Medical Centre, Jerusalem, Israel Lung Cancer Unit, Division of Oncology, Sheba Medical Center, Tel Hashomer, Israel and Group of Clinical Virology, Department of Medical Sciences, Uppsala University, Sweden
    J Thorac Oncol 9:1568-72. 2014
  10. doi request reprint A specific epitope of protein inhibitor of activated STAT3 is responsible for the induction of apoptosis in rat transformed mast cells
    Zohar Yagil
    Department of Biochemistry, Hebrew University Hadassah Medical School, Jerusalem, Israel
    J Immunol 182:2168-75. 2009

Collaborators

Detail Information

Publications21

  1. pmc A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer
    Hovav Nechushtan
    Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Oncologist 20:366-7. 2015
    ..We set out to obtain initial data regarding the safety of combining this drug with chemotherapy and the possible effectiveness of disulfiram in a combination regimen in non-small cell lung cancer (NSCLC)...
  2. doi request reprint A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients
    Hovav Nechushtan
    Oncology Dept, Hadassah Hebrew University Medical Center, Israel Electronic address
    Breast 23:435-8. 2014
    ..Use of anti EGFR-Taxane combinations should be assessed in larger clinical trials in this patient population perhaps in a similar manner to the lung cancer patients only in those with strong EGFR expression...
  3. doi request reprint The complexity of the complicity of mast cells in cancer
    Hovav Nechushtan
    Oncology, Hadassah Hebrew University Medical Center, Ein Kerem POB 12000, 91120 Jerusalem, Israel
    Int J Biochem Cell Biol 42:551-4. 2010
    ..Understanding the complex roles of mast cells in cancer should aid in understanding mechanisms of current tyrosine kinase inhibitors, and the development of innovative anti-cancer therapies...
  4. pmc Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations
    Hovav Nechushtan
    Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    BMC Cancer 9:60. 2009
    ..The differential effects of this SNP were also linked to estrogen receptor activation. Here we report on our study of 453 Ashkenazi breast cancer patients of whom 180 were positive for the known Ashkenazi BRCA1/2 mutations..
  5. pmc New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer
    Benjamin Nisman
    Department of Oncology, Hadassah and Hebrew University Medical Centre, P O Box 12000, Jerusalem 91120, Israel
    Br J Cancer 114:469-76. 2016
    ..We investigated a new plasma assay (ProGRPp) and its usefulness in diagnosing and monitoring SCLC...
  6. doi request reprint Transcription factor E3, a major regulator of mast cell-mediated allergic response
    Zohar Yagil
    Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel Canada, Hebrew University Hadassah Medical School, Jerusalem, Israel
    J Allergy Clin Immunol 129:1357-1366.e5. 2012
    ..TFE3 was previously reported to play a role in the functions of B and T cells; however, its role in mast cells has not yet been explored...
  7. ncbi request reprint Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver
    Benjamin Nisman
    Department of Oncology, Hadassah and Hebrew University Medical Center, Jerusalem, Israel
    Anticancer Res 36:1791-7. 2016
    ..The aim of this study was to investigate the prognostic value of measurements of serum TK1 activity following tumor ablation...
  8. doi request reprint Mitochondrial STAT3 plays a major role in IgE-antigen-mediated mast cell exocytosis
    Tal Hadad Erlich
    Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel Canada, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
    J Allergy Clin Immunol 134:460-9. 2014
    ..However, the regulation of mitochondrial STAT3 function and its connection to mast cell exocytosis is unknown...
  9. doi request reprint Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report
    Benjamin Nisman
    Department of Oncology, Hadassah and Hebrew University Medical Centre, Jerusalem, Israel Lung Cancer Unit, Division of Oncology, Sheba Medical Center, Tel Hashomer, Israel and Group of Clinical Virology, Department of Medical Sciences, Uppsala University, Sweden
    J Thorac Oncol 9:1568-72. 2014
    ..We aimed to assess the prognostic significance of serum TK1 activity and its role in monitoring chemotherapy in LC patients...
  10. doi request reprint A specific epitope of protein inhibitor of activated STAT3 is responsible for the induction of apoptosis in rat transformed mast cells
    Zohar Yagil
    Department of Biochemistry, Hebrew University Hadassah Medical School, Jerusalem, Israel
    J Immunol 182:2168-75. 2009
    ..This PIAS3 inhibitor peptide could serve as the beginning of an in depth study for the development of peptide inhibitors for MITF and STAT3...
  11. doi request reprint Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer
    Amir Sonnenblick
    Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Ein Kerem, P O Box 12000, Jerusalem, 91120, Israel
    Breast Cancer Res Treat 138:407-13. 2013
    ..Whether phospho-STAT3 has a predictive role of benefit from adjuvant chemotherapy has to be validated on prospective, randomized, controlled studies...
  12. doi request reprint Mast cell transcription factors--regulators of cell fate and phenotype
    Sagi Tshori
    Department of Medical Biophysics and Nuclear Medicine, Hadassah Hebrew University Medical Center, P O Box 12000, Jerusalem, 91120, Israel
    Biochim Biophys Acta 1822:42-8. 2012
    ..This article is part of a Special Issue entitled: Mast cells in inflammation...
  13. doi request reprint Mast cells and cancer--no longer just basic science
    Daliah Shoshana Tamar Galinsky
    Oncology Department, Hadassah Hebrew University Medical Center, Hadassah Ein Kerem POB 92000, Jerusalem 91120, Israel
    Crit Rev Oncol Hematol 68:115-30. 2008
    ..It seems that mast cell modulator drugs may improve the efficacy of anti-tumor therapy under certain circumstances, whilst under others, may negatively affect drug efficacy...
  14. doi request reprint Amino-acyl tRNA synthetases generate dinucleotide polyphosphates as second messengers: functional implications
    Sagi Tshori
    Department of Nuclear Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Top Curr Chem 344:189-206. 2014
    ..Recent findings established the role of dinucleotide polyphosphates as second messengers. ..
  15. ncbi request reprint A novel strategy using single-chain antibody to show the importance of Bcl-2 in mast cell survival
    Cellina Cohen-Saidon
    Department of Biochemistry, Hebrew University Hadassah Medical School, Jerusalem, Israel
    Blood 102:2506-12. 2003
    ..Moreover, it specifically neutralizes Bcl-2 intracellularly by binding to the BH1 domain and eradicates its antiapoptotic activity in 2 types of mast cells and in a human breast cancer cell line...
  16. ncbi request reprint c-Fos as a regulator of degranulation and cytokine production in FcepsilonRI-activated mast cells
    Yu Nee Lee
    Department of Biochemistry, Hebrew University, Hadassah Medical School, Jerusalem, Israel
    J Immunol 173:2571-7. 2004
    ..These findings show that c-Fos plays an important role in FcepsilonRI-mediated regulation of mast cell function...
  17. pmc Transcription factor MITF regulates cardiac growth and hypertrophy
    Sagi Tshori
    Department of Biochemistry, Hebrew University Medical School, Jerusalem, Israel
    J Clin Invest 116:2673-81. 2006
    ..Thus, for what we believe is the first time, we have demonstrated that MITF plays an essential role in beta-adrenergic-induced cardiac hypertrophy...
  18. doi request reprint EGFR mutation testing practice in advanced non-small cell lung cancer
    Jair Bar
    Department of Oncology, Institute of Oncology, Sheba Medical Center, Tel Hashomer, 52621, Ramat Gan, Israel
    Lung 192:759-63. 2014
    ..We aimed to collect data about common practice among Medical Oncologists treating lung cancer patients, regarding EGFR mutation testing in advanced NSCLC patients...
  19. doi request reprint Chapter 1: The physiological role of lysyl tRNA synthetase in the immune system
    Hovav Nechushtan
    Oncology Department, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Adv Immunol 103:1-27. 2009
    ..We begin with a short discussion of "gene sharing," proceed to a description of its structural and enzymatic function and then describe some of the in vivo functions of this enzyme...
  20. doi request reprint Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy
    Benjamin Nisman
    Department of Oncology, Hadassah and Hebrew University Medical Centre, Jerusalem, Israel
    Urology 76:513.e1-6. 2010
    ..We explored the association of their preoperative circulating levels with disease recurrence in patients with renal cell carcinoma (RCC)...
  21. ncbi request reprint [Tamoxifen and breast cancer]
    Hovav Nechushtan
    Oncology Department, Hadassah Ein Kerem, Jerusalem, Israel
    Harefuah 141:718-20, 761, 760. 2002
    ..Until new second generation SERMs and aromatase inhibitors are shown to possess better anti-cancer abilities than tamoxifen, this drug will remain in wide use, however, we must not overlook its possible rare side effects...